Functional genomics screens
CRISPR-Cas9 is an incredibly versatile tool that can be used for pooled library screening. Libraries of gRNA-targeting genes or regulatory elements can be used to find genetic loci that are critical for cancer cell survival. Utilizing this technology, we are investigating the genetic basis for drug resistance in multiple myeloma.
Patient specific epigenome mapping
Recent advances have shown how cancer relapse can be caused by epigenetic events, in addition to genetic events. We are tracking the epigenome in patient tumours in order to find the signatures that control therapy resistance. Ultimately, molecular understanding of drug resistance can allow for combination therapies that circumvent relapse.
Drugging intractable transcription factors
Master transcription factors drive gene networks that are critical for cancer cell fate. Using a combination of epigenomics and novel chemical biology approaches, we are developing tools to drug these master transcription factors.